Informed Consent in Clinical Trials: What U.S. Participants Must Know

August 16, 2026

Informed consent in clinical trials is a federally protected process, not a single signature, that requires three things from every research team: full disclosure of what the study involves, genuine facilitation of your understanding, and complete freedom from pressure to participate. The Common Rule (45 CFR 46) and FDA regulations (21 CFR 50) both mandate this, and the HHS Office for Human Research Protections (OHRP) enforces it. Before you read a single line of a consent form, know this: you have the right to take the document home, consult your doctor or family, ask every question you have, and walk away at any point without losing your medical care.

Informed consent is a process that begins before enrollment and continues throughout the trial.
Both the Common Rule (45 CFR 46) and FDA’s 21 CFR 50 govern what must be disclosed and how.
An Institutional Review Board (IRB) must approve the consent documents and process before any participant is approached.
You may withdraw at any time without penalty to your care or benefits.
OHRP and the FDA provide oversight if something goes wrong.

Key Takeaways

Informed consent in clinical trials is a federally mandated process requiring disclosure, comprehension, and voluntariness, governed by the Common Rule (45 CFR 46) and FDA regulations (21 CFR 50), with IRB oversight protecting every participant’s rights from enrollment through trial completion.

Point	Details
Consent is a process, not a form	The signed document is evidence the process occurred; the conversation, comprehension checks, and ongoing updates are the actual consent.
Ten required elements must appear	Every U.S. consent form must cover risks, benefits, alternatives, confidentiality, compensation for injury, contacts, and voluntary participation under 45 CFR 46.116 and 21 CFR 50.25.
IRBs approve before anyone is approached	No investigator may contact a potential participant until an IRB has reviewed and approved both the protocol and the consent materials.
You may withdraw at any time	Stopping participation carries no penalty and cannot affect your access to standard medical care.
HCRF and federal agencies can help	Visit HCRF at hcrfwingstocure.org for patient guides; contact OHRP or the FDA to report concerns about a consent process.

What informed consent in clinical trials actually means
The basic elements U.S. regulations require in every consent form
Who reviews and approves consent documents
When consent can be waived, altered, or delayed
Consent for people who lack capacity and other vulnerable groups
How the informed consent process typically unfolds at a trial site
What to read carefully and the questions every participant should ask
Your rights after you sign: withdrawal, new findings, and reporting concerns
Where to find official sample consent forms and key regulatory resources
How HCRF helps patients reviewing consent for cancer trials
Why the conversation matters more than the paperwork
Sources

Most people assume informed consent is the paperwork you sign before a study begins. That assumption costs participants real protection. According to FDA guidance, the consent discussion, the comprehension checks, and the ongoing exchange of new information are all part of the process. The signed form is evidence that the process happened, not the process itself.

Three features define valid consent under U.S. law:

Disclosure: The research team must share all information a reasonable person would want before deciding whether to participate, including risks, benefits, alternatives, and the voluntary nature of the study.
Understanding: The team must actively facilitate your comprehension, not simply hand you a document. Plain language, time to read, and opportunities to ask questions are all required.
Voluntariness: Your decision must be free from coercion or undue influence. No one may condition your medical care on your agreement to participate.

These three features trace directly to the Belmont Report (1979), the foundational ethical framework for U.S. research involving human subjects. The Belmont Report established respect for persons, beneficence, and justice as the governing principles, and those principles are now embedded in the Common Rule. The Declaration of Helsinki, adopted by the World Medical Association, reinforces the same framework internationally, though U.S. trials are primarily governed by federal regulations.

The distinction between clinical trial consent and routine medical consent matters. When your doctor recommends a treatment, they are acting in your individual interest, and the standard is what a reasonable clinician would disclose. In a clinical trial, the research team has a dual obligation: to you as a participant and to the integrity of the science. That tension is precisely why federal regulations and IRBs exist. As StatPearls summarizes, informed consent is mandatory for all clinical trials involving human beings, and IRBs monitor adherence continuously.

Consent also does not end at enrollment. If new findings emerge during the trial that a reasonable person would want to know, the research team is obligated to inform you, and in many cases you will be asked to re-consent before continuing.

45 CFR 46.116 and 21 CFR 50.25 specify the minimum information every consent document must contain. Here is each element in plain language:

Statement that the study involves research. The form must say explicitly that you are being invited to participate in a research study, not routine care.
Purpose, duration, and procedures. What the study is trying to find out, how long your participation will last, and exactly what will be done to or with you, including which procedures are experimental.
Foreseeable risks or discomforts. All reasonably foreseeable risks must be described, not minimized. This includes physical, psychological, social, and financial risks.
Expected benefits. Benefits to you or to others must be stated honestly. If there is no direct benefit to you, the form must say so.
Alternatives to participation. You must be told what other treatments or options exist outside the trial, so you can make a genuinely informed choice.
Confidentiality. How your records will be protected, who may see them (including the FDA and sponsors), and any limits on confidentiality must be explained.
Compensation and treatment for injury. If the study involves more than minimal risk, the form must explain whether compensation or medical treatment is available if you are harmed, and where to get more information.
Contacts. Names and phone numbers for questions about the research, your rights as a participant, and whom to call in an emergency.
Voluntary participation. A clear statement that participation is voluntary, that refusal carries no penalty, and that you may stop at any time without losing benefits to which you are otherwise entitled.
ClinicalTrials.gov disclosure statement. For applicable clinical trials initiated on or after March 7, 2012, the consent form must include a statement that a description of the trial will be posted on ClinicalTrials.gov. This requirement comes from 21 CFR 50.25© and is detailed in FDA guidance.

The Common Rule adds one more structural requirement that is easy to overlook: the consent document must begin with a concise key-information section presenting the facts a reasonable person would most want to know, in a way that facilitates comprehension. Regulators specifically prohibit exculpatory language, meaning any wording that asks you to waive your legal rights or release the sponsor from liability for negligence.

Pro Tip: Before reading the full consent form, flip to the key-information section at the front. If it is missing or buried, ask the research coordinator to walk you through the most important risks and procedures verbally before you read anything else.

An Institutional Review Board is an independent committee, required by federal law, that reviews and approves all research involving human subjects before it begins. IRBs evaluate the consent process and documents, the risk-to-benefit ratio, and whether special protections are in place for vulnerable populations. No investigator may approach a potential participant until the IRB has approved both the protocol and the consent materials.

A few things participants often misunderstand about IRBs:

The IRB approves the consent process and documents, but a member of the research team, usually a physician, nurse, or trained coordinator, is the person who actually conducts the consent conversation with you.
IRB approval does not mean the study is risk-free. It means the risks have been reviewed and judged acceptable relative to the potential benefits, and that the protections in place are adequate.
IRBs conduct continuing review throughout a trial. If new safety data emerges, the IRB can require protocol changes, additional disclosures, or re-consent of enrolled participants.

Federal oversight adds another layer. OHRP, within HHS, provides regulatory guidance and investigates complaints about research conducted under the Common Rule. The FDA has parallel authority over trials involving drugs, biologics, and devices. Both agencies can audit IRBs, require corrective action, or suspend research. OHRP’s informed consent FAQs are one of the clearest plain-language resources available for understanding how these protections work in practice.

Sponsors, the companies or institutions funding the trial, also review consent documents, but their review is subordinate to IRB approval. A sponsor cannot override an IRB’s requirement for additional disclosures.

The regulations allow narrow exceptions, and understanding them matters because you may encounter a study that did not obtain your consent in the usual way.

Waiver or alteration of consent elements under the Common Rule requires the IRB to find all four of the following:

The research involves no more than minimal risk.
The waiver or alteration will not adversely affect participants’ rights and welfare.
The research could not practicably be carried out without the waiver or alteration.
Participants will be provided with pertinent information after participation, when appropriate.

Waiver of documentation (the signature requirement) is a separate, narrower question. An IRB may waive the requirement for a signed consent form when the form would be the only record linking you to the research and the principal risk is a breach of confidentiality, or when the research involves minimal risk and participants would not normally sign a form for non-research activities of the same type.

Emergency research exceptions are governed by 21 CFR 50.24 and a parallel HHS Secretarial waiver provision. These apply when a life-threatening situation prevents a person from giving consent, no LAR is available, time is insufficient to obtain consent, and the research could not otherwise be done. The conditions are strict: the IRB must prospectively approve the protocol, the community must be notified in advance, and participants or their representatives must be informed as soon as possible after enrollment.

Short form consent is not a waiver. It is an alternative documentation method for participants who do not read English. A short form, written in the participant’s language, summarizes that the required elements have been presented orally. A witness must be present for the oral presentation, and the IRB-approved English summary must be provided. The research vs. clinical grade distinctions that apply to procedures and materials also apply here: the short form is a research-specific tool, not a substitute for a full consent process.

Not every participant can give legally valid consent independently, and the regulations address this directly.

Legally authorized representatives (LARs) may consent on behalf of someone who lacks the capacity to do so, such as a person with advanced dementia or a serious acute illness. Who qualifies as a LAR varies by state law, and the research team must follow the applicable state definition. Common LARs include spouses, adult children, parents, and court-appointed guardians. LAR consent carries the same disclosure and voluntariness requirements as direct consent.

Representative holding patient's wrist

Minors require a different framework. Parents or guardians provide permission, and the child provides assent, meaning an affirmative agreement to participate that goes beyond simply not objecting. The IRB determines whether assent is required based on the child’s age, maturity, and psychological state. When a study offers the prospect of direct benefit available only through the research, the IRB may waive the assent requirement. Both parental permission and child assent should be documented separately.

Prisoners are a specially protected population under Subpart C of 45 CFR 46. Research involving prisoners requires additional IRB review and must meet specific criteria about the nature of the research and the protections in place. The concern is that the prison environment may compromise voluntariness.

Other groups that receive heightened attention include pregnant people (Subpart B), individuals with cognitive impairments, and people in dependent relationships with investigators, such as students or employees. For these groups, IRBs look carefully at whether the consent process adequately minimizes the risk of coercion or undue influence. The role of ethics in critical care settings offers useful context on how these vulnerability considerations play out in time-sensitive clinical environments.

Knowing the sequence helps you prepare and advocate for yourself at every step.

Pre-screening. Before you are formally approached for consent, the research team may review your medical records or ask brief eligibility questions. Some protocols require separate permission for this pre-screening step. Ask whether the pre-screening itself is covered by the main consent form or requires a separate authorization.
Receiving the consent form. Once you are identified as potentially eligible, you receive the IRB-approved consent form and any supplemental information sheets. Federal rules require that you be given sufficient time to consider participation and to minimize coercion. You are entitled to take the document home and consult your physician, family members, or anyone else before deciding.
The consent conversation. A qualified member of the research team, often the principal investigator or a trained coordinator, walks through the form with you. This is not a formality. Ask every question you have. The team is required to answer them and to check that you understand before asking you to sign.
Documentation. The most common format is a full written consent form with your signature and the date. Electronic consent (eConsent) is increasingly used and is acceptable under FDA guidance when it meets the same disclosure and comprehension standards. For non-English speakers, the short form process described above applies. The research team should also document the consent interaction in the source record, noting when and where the discussion occurred, who was present, how long it lasted, and that questions were answered.
Re-consent. If the protocol changes in a way that affects your participation, or if new safety information emerges, the research team must inform you and, in most cases, ask you to sign an updated consent form before continuing. Re-consent is not a sign that something went wrong; it is the system working as intended.

Pro Tip: Bring a trusted person to the consent visit. Two sets of ears catch more than one, and having someone with you reduces the pressure to decide on the spot. Write your questions down beforehand so you do not forget them in the moment.

What to read carefully and the questions every participant should ask

The consent form can run 20 or more pages. These are the sections that carry the most weight.

Critical sections to read with care:

Risks and discomforts: Read every risk listed, including rare ones. Ask how often each has occurred in earlier studies.
Procedures: Confirm which procedures are experimental versus standard care, and how many extra visits or tests the study requires.
Time commitment: Calculate the total hours, including travel, and decide whether that is realistic for your life.
Costs and insurance: Clarify which costs the sponsor covers and which may fall to you or your insurer.
Compensation: Understand exactly what you will receive and when, and whether compensation is contingent on completing the study.
Withdrawal policy: Confirm that leaving the study will not affect your access to standard medical care.
Exculpatory language: If you see any sentence that sounds like you are giving up your right to sue or releasing the sponsor from all liability, flag it immediately. That language is prohibited under the Common Rule.

Questions to ask the research team:

What is the study trying to find out, and how will the results be used?
What are the most serious risks, and how likely are they based on earlier data?
What happens if I am harmed? Will the sponsor cover my medical costs?
Is there a placebo group, and how will I know which group I am in?
Can I continue my current medications and treatments?
Who will have access to my medical records and personal data?
What happens to my care if the trial ends early?
How will I receive updates about new findings during the study?
What does withdrawal look like operationally? Do I need to taper off any study drug?
Who do I call if I have a problem at 2 AM on a Saturday?

A compliance checklist for research labs tied to 45 CFR 46.116 and 21 CFR 50.25 can help you cross-reference whether the form you received covers every required element.

Your rights after you sign: withdrawal, new findings, and reporting concerns

Signing the consent form is not a contract. Your rights continue for the entire duration of the trial.

Withdrawal is unconditional. You may stop participating at any time, for any reason, without penalty or loss of benefits to which you are otherwise entitled. Operationally, withdrawal may involve a safety follow-up visit or a tapering schedule for study drugs, but those steps exist for your protection, not to make leaving difficult. Ask the research team at the consent visit exactly what withdrawal looks like for this specific study.

New findings. If significant new information emerges during the trial, such as a newly identified risk or a change in the risk-benefit balance, the investigators are obligated to tell you. When the new information is material enough that a reasonable person might reconsider participation, the team will ask you to re-consent. You are never obligated to continue simply because you signed an earlier form.

Reporting concerns. If you believe your rights have been violated or the consent process was inadequate, you have several pathways:

The IRB that approved the study. Contact information must appear on your consent form.
OHRP, for research conducted under the Common Rule. OHRP accepts complaints and investigates noncompliance.
The FDA, for trials involving drugs, biologics, or devices regulated by the agency.
The research institution’s research compliance office.

Injury compensation. The consent form is required to explain whether compensation or medical treatment is available if you are harmed. Read that section carefully before signing. Many U.S. trials do not provide automatic compensation for research-related injuries, and the form must say so explicitly if that is the case. Ask the team to explain the injury compensation policy in plain language before you sign.

Several authoritative sources publish templates, sample language, and plain-language guides that you can use to cross-check the consent form you receive at a trial site.

Official resources:

NCI (National Cancer Institute): Publishes sample informed consent documents and plain-language templates specifically for cancer trials. These are available through the NCI’s clinical trials website and are widely used by cancer research centers, including those affiliated with academic medical centers.
OHRP: Maintains a detailed FAQ on informed consent requirements under the Common Rule, covering everything from waiver criteria to documentation rules. The OHRP website also links to the full regulatory text of 45 CFR 46.
FDA: The FDA’s informed consent guidance document covers regulatory requirements for FDA-regulated trials, short-form procedures, eConsent, and the ClinicalTrials.gov statement requirement.
ClinicalTrials.gov: Provides plain-language explanations of what clinical trial participation involves and hosts trial records that include the required disclosure statement. Searching a trial’s NCT number on ClinicalTrials.gov gives you the sponsor’s own description of the study, which you can compare to what the consent form says.

Regulatory posting and timing rules:

Requirement	Rule	Timing
ClinicalTrials.gov disclosure statement in consent	21 CFR 50.25©	Required for applicable trials initiated on or after March 7, 2012
Posting of IRB-approved consent form (federally supported trials)	45 CFR 46.116(h)	Must be posted after recruitment closes, within the period specified by regulation
Re-consent when new material information emerges	IRB and investigator obligation	Before participant continues after the change
Short form consent (non-English speakers)	45 CFR 46	At time of consent; witness required for oral presentation

How to use templates. Download the NCI sample consent form or the OHRP model language and place it side by side with the form you received. Every required element should appear somewhere in your form. If a section is missing or the language seems to release the sponsor from liability, raise it with the research team or the IRB before signing.

The Hippocratic Cancer Research Foundation (HCRF) is a 501©(3) nonprofit that funds “out of the box” cancer research at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Beyond funding, HCRF produces patient-facing educational content designed to help people understand what clinical trial participation actually involves, including the consent process.

Ways HCRF supports patients navigating consent:

Educational guides on specific trial types. HCRF publishes detailed, plain-language guides on cancer-specific trials, including resources on immunotherapy trials for lung cancer, pancreatic cancer immunotherapy trials, and prostate cancer immunotherapy trials. Each guide explains what participation involves and what questions to ask.
Practical patient guidance. Resources like the foundation’s guide on supplements to avoid during immunotherapy reflect HCRF’s commitment to giving patients the specific, actionable information they need before and during trial participation.
Connection to research and funding. HCRF’s work in breast cancer research funding and other areas means the foundation has direct insight into how trials are designed and what participants can expect.
Direct access to the HCRF team. Patients and families can reach out through the HCRF website for guidance on navigating cancer trial resources and understanding what the consent process should look like.

If you or someone you love is reviewing a consent form for a cancer trial and you are not sure what you are reading, HCRF’s educational resources are a good starting point before you sit down with the research team.

Why the conversation matters more than the paperwork

There is a quiet assumption embedded in how most institutions handle consent: that a signed form means a participant understood. The research on this is humbling. Studies of consent comprehension consistently find that participants retain far less than investigators assume, particularly around risks and the distinction between research and treatment. The form is necessary, but it is not sufficient.

What actually protects participants is the quality of the conversation that surrounds the form. A research team that reads the document aloud, pauses to check comprehension, invites questions, and schedules a follow-up call before the enrollment visit is doing something categorically different from one that hands over a 30-page document and asks for a signature by end of day. Both may be technically compliant. Only one is genuinely ethical.

The most overlooked protection in the entire consent framework is the right to take the form home. Federal rules require sufficient time to consider participation, and no legitimate research team will pressure you to sign on the spot. If you feel rushed, that is a red flag worth acting on, not ignoring.

For cancer patients especially, the emotional weight of a diagnosis can make any offered treatment feel urgent. That urgency is real, and it is also exactly the condition under which voluntariness is hardest to protect. Asking for 48 hours to review the form with your oncologist and a family member is not an obstacle to research. It is the system working as it was designed.

Sources

These are the primary documents and sites this article draws from. Each is freely accessible and represents the authoritative source for its area.

Regulations and guidance documents are different things. The CFR text is binding law. FDA and OHRP guidance documents explain how agencies interpret and apply that law, but they are not themselves regulations. When a consent form or research team cites “guidance,” ask which specific document they mean and whether it reflects current agency thinking.

News